Rapid development of a lead aromatic aldehyde derivative with both oxygen dependent and novel, oxygen independent anti-sickling effects: building on a paradigm shift in sickle cell disease therapy
Ended Project Grant Awarded Last action
- Award ID
- R43HL154864
- Recipient
-
Illexcor Therapeutics, Inc. UEI GFKZPH9N1VX3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,984
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- Virginia, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$8 | |
| Amendment | -$8 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $300,000 |
Quick answers
Who received award R43HL154864?
R43HL154864 was awarded to Illexcor Therapeutics, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 15, 2020.
How much is award R43HL154864 worth?
$299,984 has been obligated on R43HL154864.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award